Predictive biomarkers help to identify tumors that are most likely to benefit from a specific treatment and spare patients from toxic effects of ineffective therapies. Both genetic mutations and protein levels in diseased tissues are examples of predictive biomarkers, yet few platforms enable the simultaneous evaluation of both RNA and protein.
The GeoMx Digital Spatial Profiler (DSP) from NanoString provides morphological context in spatial transcriptomics and spatial proteomics experiments for immuno-oncology research. The GeoMx DSP platform can investigate novel biomarkers in tissue samples because it offers digital profiling of protein and RNA analytes on the same slide.
This application note from Canopy Biosciences, a Center of Excellence for NanoString services, outlines a recent study that used the GeoMx DSP to investigate novel biomarkers associated with beneficial PD-1 therapy in formalin-fixed, paraffin-embedded samples from patients with non-small cell lung cancer.
Offered Free by: Bruker Scientific
See All Resources from: Bruker Scientific